Have confidence in any liquid biopsy workflow

Commutable cell-free DNA controls

Liquid biopsy is still developing as a key focus of genome evaluation, due to its minimally invasive nature. To support this ongoing development, robust controls are needed to take liquid biopsy from assay development through to routine monitoring in the clinic. Our cell line-derived cfDNA reference standards mimic circulating tumor DNA in clinical samples.

Allele frequencies as low as 0.1%
  • Be confident in your limits of detection
  • Control for the variable frequency of clinical samples with a range of allele frequencies